Next Article in Journal / Special Issue
Current View in Platinum Drug Mechanisms of Peripheral Neurotoxicity
Previous Article in Journal / Special Issue
Cisplatin-Induced Ototoxicity: Effects, Mechanisms and Protection Strategies
Open AccessReview

An Overview of Bortezomib-Induced Neurotoxicity

Experimental Neurology Unit, Department of Surgery and Translational Medicine, University of Milan-Bicocca, Via Cadore 48, 20900 Monza (MB), Italy
Academic Editor: Cheng Wang
Toxics 2015, 3(3), 294-303;
Received: 13 May 2015 / Revised: 15 July 2015 / Accepted: 21 July 2015 / Published: 27 July 2015
(This article belongs to the Special Issue Toxicities of Therapeutic Agents Used in Medicine)
The boronic acid dipeptide bortezomib, able to induce tumor cell death by degradation of key proteins, is the first proteasome inhibitor drug to enter clinical practice. It is employed as first-line treatment in relapsed or resistant multiple myeloma (MM) patients. However, bortezomib often induces a dose-limiting toxicity in the form of painful sensory neuropathy, which can mainly be reduced by subcutaneous administration or dose modification. In this review we focus on the current understanding of the pathophysiological mechanisms of bortezomib-induced neuropathy to allow further studies in animal models and humans, including analysis of clinical and pharmacogenetic aspects, to optimize the treatment regimens. View Full-Text
Keywords: bortezomib-induced neurotoxicity; multiple myeloma; long-term effects; neuropathic pain bortezomib-induced neurotoxicity; multiple myeloma; long-term effects; neuropathic pain
Show Figures

Figure 1

MDPI and ACS Style

Meregalli, C. An Overview of Bortezomib-Induced Neurotoxicity. Toxics 2015, 3, 294-303.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop